These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
195 related items for PubMed ID: 22244544
1. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Siegal T, Goldschmidt N. Blood Rev; 2012 May; 26(3):97-106. PubMed ID: 22244544 [Abstract] [Full Text] [Related]
2. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST. Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246 [Abstract] [Full Text] [Related]
5. Central nervous system involvement in diffuse large B-cell lymphoma. Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y. Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301 [Abstract] [Full Text] [Related]
6. CNS prophylaxis in lymphoma: who to target and what therapy to use. Hill QA, Owen RG. Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838 [Abstract] [Full Text] [Related]
9. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Korfel A. Curr Opin Oncol; 2011 Sep; 23(5):436-40. PubMed ID: 21760506 [Abstract] [Full Text] [Related]
10. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681 [Abstract] [Full Text] [Related]
11. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C. Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190 [Abstract] [Full Text] [Related]
15. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K. Cancer Sci; 2012 Feb; 103(2):245-51. PubMed ID: 22044593 [Abstract] [Full Text] [Related]
17. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A. Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228 [Abstract] [Full Text] [Related]
18. Prevention of CNS relapse in diffuse large B-cell lymphoma. Kridel R, Dietrich PY. Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751 [Abstract] [Full Text] [Related]
19. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors]. Sancho JM, Ribera JM, Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL. Med Clin (Barc); 2016 Jan 15; 146(2):74-80. PubMed ID: 25817451 [Abstract] [Full Text] [Related]
20. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis. Lin Z, Chen X, Liu L, Zeng H, Li Z, Xu B. Crit Rev Oncol Hematol; 2022 Aug 15; 176():103756. PubMed ID: 35809794 [Abstract] [Full Text] [Related] Page: [Next] [New Search]